Results 41 to 50 of about 38,476 (212)

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study [PDF]

, 2013
OBJECTIVE: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. DESIGN: Pharmacoepidemiological cohort study.
Charlot, M., Fosbol, E. L., Gislason, G., Hansen, M. L., Hvidtfeldt, M. W., Karasoy, D., Kober, L., Lamberts, M., Lip, G. Y. H., Olesen, J. B., Sorensen, R., Torp-Pedersen, C., Weeke, P.   +12 more
core   +1 more source

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

Рациональная фармакотерапия в кардиологии, 2016
Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj   +1 more source

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2

Российский кардиологический журнал, 2020
Aim. To analyze clinical characteristics of patients with nonvalvular atrial fibrillation (AF) in the Russian population, enrolled in the GLORIA-AF registry phase 2, depending on the antithrombotic therapy received, and to assess the potential for ...
E. V. Shlyakhto, S. V. Villevalde, A. V. Ezhov, S. A. Zenin, N. A. Koziolova, O. Yu. Korennova, T. N. Novikova, K. V. Protasov, G. A. Chumakova, C. Teutsch, S. Lu, G. Y. H. Lip, M. V. Huisman   +12 more
doaj   +1 more source

Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. [PDF]

PLoS ONE, 2016
Dabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA).
J Stevanović, L A de Jong, B S Kappelhoff, E P Dvortsin, M Voorhaar, M J Postma   +5 more
doaj   +1 more source

Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C [PDF]

, 2014
AIMS: Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes.
Berit P. Jensen, Daniel F. B. Wright, David M. Patterson, Evan J. Begg, Mary C. Wallace, Mei Zhang, Murray L. Barclay, Paul K. L. Chin, Rebecca L. Roberts   +8 more
core   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation

BMC Cardiovascular Disorders, 2022
Background This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF).
Zhu Zhu, Chenyue Qian, Cunjing Su, Hong Tao, Jiaojiao Mao, Zhening Guo, Xinyi Zhu, Jie Pan   +7 more
doaj   +1 more source

Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]

, 2018
Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson, Annemans, Arya, Barco, Bischof, Bjorvatn, Botteman, Braidy, Brockbank, Capri, Caprini, Cohoon, Curtis, Dahl, Dahl, Davies, Diamantopoulos, Dranitsaris, Dranitsaris, Ende-Verhaar, Gomez-Outes, Gordois, Gould, Haentjens, Hamidi, Hauck, Heit, Husereau, Jameson, Jameson, Kahn, Kapoor, Lundkvist, McCullagh, McCullagh, McDonald, Migliaccio-Walle, Postma, Quinlan, Reeves, Revankar, Riemsma, Roberts, Ryttberg, Sterne, Stevenson, Wade, Wang, Warwick, White, Wille-Jørgensen, Wolowacz, Wolowacz, Zindel   +53 more
core   +4 more sources